Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), an ... acquiring cutting-edge technology, products and services announced today that ... booth # 709 at the National Association of ... March 11-13, 2015 at Caesars Palace in ... 36 th annual NAPNAP Conference will bring over ...
(Date:3/5/2015)... , March 5, 2015  AMRI (NASDAQ: ... , fills the newly created position of VP of ... Conway , Senior Vice President of Global Sales and ... will lead the international sales team in an effort ... in targeted market segments. Mr. Pettersson will drive strategy ...
(Date:3/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ... Pharma Outlook 2015: Accelerating growth to the next level ... report to their offering. Domestic sales ... 2013 caused by the market,s reaction to the new ... continue to be healthy, as the momentum continues and ...
Breaking Medicine Technology:Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3AMRI Hires VP of International Sales 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3
... insights into global patent and trademark trends with the ... brand protection trends throughout 2011. The two reports, ... Their States of Innovation and ... track patent and trademark activity in key technology ...
... March 10, 2012 Omnicell, Inc ., (NASDAQ: ... medication and supply management solutions and analytics software for ... the Dubai International Pharmaceuticals and Technologies Conference and Exhibition ... Exhibition Centre. DUPHAT is one of the most recognized ...
Cached Medicine Technology:Patent and Trademark Trends 2011: Thomson Reuters Evaluates the State of Global IP 2Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition 2
(Date:3/6/2015)... Nolen, the largest family-owned pest control company in America, ... first independently-owned and operated franchise in North Carolina, serving ... Rock Hill, SC area. The ribbon cutting ceremony was ... , The Truly Nolen Carolina team has ... control industry. Locally owned and operated by local Charlotteans, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 You ... company, created a unique ‘energy’ experiment to determine ... , After quick ‘5 -7 minute’ ... than 150+ countries reported their life improving - ... reported positive results. , According to research, respondents ...
(Date:3/6/2015)... Fluid Running® Owner, Jennifer Conroyd, an ... Fluid Running® method 3 years ago when ... She hit upon the trifecta of combining matched-bpm music, ... maximum-resistance, deep water running technique. She not only completed ... running workout that made the experience both enjoyable and ...
(Date:3/5/2015)... London, UK (PRWEB) March 06, 2015 ... of them being first–in-class. AstraZeneca tops the list scoring ... field obtained over 25% of all FDA approved drug ... total. First-in-class mechanisms such as anti-PCSK9, anti-PD1 and CDK ... have been approved by the FDA to treat metastatic ...
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a ... repair market, reported record revenue of $4.79 million for ... $2.98 million in the year-ago fourth quarter demonstrating the ... “Our strong fourth quarter revenue growth reflects the market’s ... is driving increased surgeon adoption of our unique product ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... and start over after they,ve been denied disability benefits; Allsup explains the ... ... 31, 2008 -- Getting a denial letter after hours of work and ... call it quits, according to Allsup , which represents people nationwide ...
... such study ever published finds that, while about 40 ... 12 percent indicate that those issues are a source ... a Massachusetts General Hospital (MGH) physician appears in the ... , "Sexual problems are common in women, but problems ...
... Attributes Innovation to its 385 Percent Revenue Growth, ... Health Market Science,Inc. has been named to Deloitte,s ... of the 50 fastest growing technology, media,telecommunications and ... LLP,one of the nation,s leading professional services organizations. ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), a leading provider ... present at November,investment conferences hosted by Oppenheimer & Co., Credit ... from:, -- 1:20 p.m. to 1:55 p.m. ... & Co. 19th Annual Healthcare Conference in ...
... researchers say , , THURSDAY, Oct. 30 (HealthDay News) -- ... years, but heavy metal contamination found in some European ... into a hazard, British researchers report. , Heavy metals ... disease and may also increase oxidative stress, which can ...
... for a four-star ease of use ... rear and front facing positions!, OAK BROOK, Ill., Oct. ... RC2 Corporation (Nasdaq: RCRC ),( http://www.learningcurve.com ), was recently ... First Years True,Fit C630 Convertible Car Seat a four-star Ease ...
Cached Medicine News:Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 2Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 3Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 4Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 6Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Health Market Science, Inc. Ranked Number 17 in Deloitte's Fast 50 Program for Greater Philadelphia 2Health News:Health Market Science, Inc. Ranked Number 17 in Deloitte's Fast 50 Program for Greater Philadelphia 3Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 2Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 3Health News:Heavy Metals Can Taint Wine 2Health News:Heavy Metals Can Taint Wine 3Health News:The First Years True Fit C630 Convertible Car Seat Recieves Highest Given Rating From the National Highway Traffic Safety Administration 2
Curved shafts with delicate 1 x 2 teeth. Serrated handle. Polished finish....
Inner jaw space 2.0 mm - 45 degree tip angulation. 20 gauge (.89 mm) diameter shaft and stationary distal jaw. Lightweight squeeze handle with dull finish. Jaws 1.5 mm serrated....
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with heavy 1 x 2 teeth. Non-magnetic with serrated handle and polished finish....
Medicine Products: